RT Journal Article
SR Electronic
T1 Optimal and worst testing strategies for COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.31.21262868
DO 10.1101/2021.08.31.21262868
A1 Onishi, Tatsuki
A1 Honda, Naoki
A1 Igarashi, Yasunobu
YR 2022
UL http://medrxiv.org/content/early/2022/07/15/2021.08.31.21262868.abstract
AB Background During the last three years of fighting COVID-19, governments have been seeking optimal solutions to minimize the negative impacts on societies. They actively used mathematical models such as the susceptible, infectious, exposed, recovered, and dead (SEIRD) model to predict the spread of infection. However, in the end, all governments had difficulty figuring out how to adopt testing strategies.Methods In this study, we developed a testing-SEIRD model, which incorporates testing strategy and testing characteristics. In this model, people who are tested positive are admitted to the hospital within the capacity and medical resources. Through simulations, we examined the infection spread depending on the balance between follow-up testing and mass testing, which test people closely contacted with infected persons and people with symptoms, respectively.Results We showed that there are optimal and worst combinations of the follow-up and mass testing. These strategies are subject to total resources and cost ratio of testing costs. We also found that these combinations provide an all-or-nothing response for whether the spread of infection expands or extinguishes.Conclusions While this model alerts us to the existence of a worst testing strategy, it also reveals that an optimal testing strategy can lead to infection containment. Therefore, the testing-SEIRD model is useful in making decisions on testing strategies for the emerging infectious disease outbreaks.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partly supported by the Cooperative Study Program of Exploratory Research Centre on Life and Living Systems (ExCELLS) (program Nos.18-201, 19-102, and 19-202 to H.N.), a Grant-in-Aid for Transformative Research Areas (B) [grant number 21H05170], a Grant-in-Aid for Scientific Research (B) (21H03541 to H.N.) from the Japan Society for the Promotion of Science (JSPS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Exempted from ethical review because no human or animal subjects or specimens are involved.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the study and its supporting information files. https://github.com/bougtoir/testing-SEIRD